<DOC>
	<DOCNO>NCT02497131</DOCNO>
	<brief_summary>This single-arm , open-label , multicenter , clinical trial evaluate efficacy safety Brentuximab Vedotin ( BV ) single agent relapsed/refractory CD30+ PTCL patient . BV administer single IV infusion Day 1 21-day cycle . Measures anti-cancer activity assess use revise response criterion malignant lymphoma ( Cheson et al . 2007 ) . Computed tomography ( CT ) scan ( chest , neck , abdomen , pelvis ) PET scan perform baseline Cycles 3 , 8 , 12 , 16 . Patients End Treatment ( EOT ) assessment 30 ± 7 day receive final dose study drug . Patients least stable disease enter short follow phase till month 24 radiology assessment every 6 month visit every 12 week . After month 24 patient progressive disease , long-term follow-up assessment ( include survival , disease status next therapy information ) perform every 12 week either patient death study closure , whichever occur first .</brief_summary>
	<brief_title>Study Role Brentuximab Vedotin Single Agent Treatment Relapsed/Refractory CD30+ PTCL Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphatic Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed write informed consent . Males females ≥18 ≤75 year time enrolment . Histologically confirm diagnosis PTCL ( PTCLnot otherwise specify [ PTCLNOS ] , angioimmunoblastic T cell lymphoma [ AILT ] transform mycosis fungoides ) accord World Health Organization ( 2008 ) classification . Histologically confirm CD30+ PTCL . Availability histological material central review pathobiological study . Failed least one prior systemic antilymphoma therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 1 study entry . At least one site disease measurable two dimension compute tomography . Both nodal extranodal disease consider ( lymphnodes must long axis 1.5 cm regardless short axis long axis 1.1 1.5 cm short axis &gt; 1.0 cm ) . Hematology value within follow limit : Absolute neutrophil count ( ANC ) ≥ 1500/mm3 independent growth factor support . Platelets ≥75,000/mm3 ≥50,000/mm3 bone marrow involvement independent transfusion support . Hemoglobin level ≥8 g/dL . Biochemical value within follow limit : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 3 x upper limit normal ( ULN ) . Total bilirubin &lt; 1.5 x ULN ( unless bilirubin rise due Gilbert 's syndrome nonhepatic origin ) . Serum creatinine ≤ 2 x ULN . Serum albumin ≥ 3 g/dL . Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day receive study medication . WOCBP must agree use effective contraception , define oral contraceptive , double barrier method practice true abstinence sexual intercourse study 6 month last dose study drug . Male subject female partner childbearing potential must willing use appropriate method contraception practice true abstinence sexual intercourse study 6 month last dose study drug . Diagnosis CTCL , ALCL , mycosis fungoides Sezary Syndrome . CD30 expression &lt; 10 % measure IHC Patients complete prior treatment chemotherapy and/or investigational agent within least 5 halflives last dose prior treatment . Patients underwent major surgery without complete recovery Known hypersensitivity recombinant protein , murine protein , excipient contain drug formulation brentuximab vedotin . Any serious active disease comorbid medical condition ( accord investigator 's decision ) . Prior history malignancy lymphoma ( except history complete resection basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year . Patients peripheral neuropathy grade 34 . Signs symptom progressive multifocal leukoencephalopathy ( PML ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>PTCL</keyword>
	<keyword>CD30+</keyword>
</DOC>